Octave Accelerates Leadership in Precision Care with Addition of World-Class Commercial Executives More

Our Science

Powerful innovation to transform MS

We're committed to rigorous and ongoing evaluation.

Browse our latest publications below.

Category

1 2 … 8

Predictive Utility of Serum Protein Biomarkers from the Octave MSDA Panel for Optic Neuritis Events in People with Multiple Sclerosis

Research Presented at AAN 2024

Novel Visualization of the Topographical Model of Multiple Sclerosis Using 3D Rendering of Quantified MRI

Research Presented at AAN 2024

Improving Patient Outcomes Through a Comprehensive Care Platform in MOVING-MS – A Case Study

Research Presented at ACTRIMS 2024 - February 29 - March 1

Measuring Outcomes and Value: an Integrated, Novel Solution for Generating insights in MS (MOVING MS)

Research Presented at ACTRIMS 2024 - February 29 - March 1

Safety and Effectiveness of Cladribine Tablets After Treatment With Natalizumab (CLADRINA) Trial – Interim Analysis

Research Presented at ACTRIMS 2024 - February 29 - March 1

Real-World Utilization of a Proteomic Biomarker Panel for Assessing Multiple Sclerosis Disease Activity in an Academic Multiple Sclerosis Clinic with a Diverse Patient Population

Research Presented at ACTRIMS 2024 - February 29 - March 1

Evaluating the Impact of Manual Editing on Automated MRI Lesion Segmentation in Multiple Sclerosis

Research Presented at ACTRIMS 2024 - February 29 - March 1

Discrepancies in the Detection of Salient MS Lesion Counts Between Neuroradiologists and Manually Corrected Automated Lesion Segmentation

Research Presented at ACTRIMS 2024 - February 29 - March 1

Comparison of Natalizumab, Ocrelizumab, and Diroximel Fumarate in RRMs Patients Stable on Therapy to Characterize Proteomic, Radiomic, and Clinical Trajectories: Study Design

Research Presented at ACTRIMS 2024 - February 29 - March 1

Bridging Proteomics to the Clinic – A Multivariate Blood Test for Disease Activity in Multiple Sclerosis

Research presented at HUPO - September 17-21 2023